Technical accounting memos, explained.

What a technical accounting memo is: the written reason behind one hard number

From a signed contract to the audit file: the five stops of an accounting question

1. A deal closesA license, an acquisition or a collaboration is signed. In the example, the license is signed on August 30, 2026.
2. Someone asks the questionA deal or alliance accountant asks how it should be booked, usually while the quarter is closing.
3. Research and draftingA technical accountant reads the contract, the policy manual, earlier memos and the ASC, then writes the position. This step is what this guide is about.
4. Review and signatureA second reader challenges it. The controller signs, and on larger items the chief accounting officer signs too.
5. The auditors test itThe memo goes to the external auditor, and significant judgments go to the audit committee of the board. In the example, on October 16 and October 28.

The people, companies and figures in this example are fictional.

No rule demands a memo, and three more surprises about position papers

The vocabulary of a position memo: variable consideration, constraint, IPR&D and the screen test

Fourteen terms are defined in the summary and glossary.

Technical accounting memo template: the eight parts of a position memo and which readers rely on each

In shortA good memo has a recognizable shape: purpose, facts, literature, analysis, alternatives, conclusion, financial statement impact and sign-off. Each part serves a different reader. The analysis works best when it follows the steps of the standard itself, because that is how an auditor will check it.

The sample company in this guide uses a house template with eight sections. No rule fixes the format, so other teams' templates will differ. The order matters less than whether a stranger can follow the reasoning, which is also how SEC guidance frames it: documentation should allow a third party, such as the external auditor, to consider the work management did.1

Eight memos in one biotech's third quarter, sized by the money at stake

Volume surprises people outside finance. In the guide's fictional company, one quarter of deal activity produces eight position memos on eight different standards. Few companies publish such a list, so treat this as an example of the mix and count your own.

The accounting rules behind a position memo, with what changed through November 2026

In shortThe core revenue, acquisition and research standards have held steady for years. What moved sits around them: a September 2025 change to derivatives scope that touches milestone-linked contracts, new expense and interim disclosures, shorter audit documentation deadlines, new control guidance for generative AI, and an SEC proposal to make quarterly reports optional, with no final rule found.

Three bodies appear in this section. The Financial Accounting Standards Board, or FASB, writes US GAAP and changes the ASC through documents called Accounting Standards Updates, or ASUs. The SEC sets reporting rules for public companies. COSO, the Committee of Sponsoring Organizations of the Treadway Commission, publishes a well-established framework for internal control.5

If quarterly reports become optional, memos stay

Under the SEC's proposal, a company could choose to file a Form 10-S for the first six months of its fiscal year in place of three Form 10-Q quarterly reports. The form would carry the same information, due in the same 40 or 45 days. An independent accountant would still review the statements, and the current certifications on controls would still apply.15

A company that opts in would have fewer forced reporting dates, while its deals would keep closing at the same pace. A company that later switches back to quarterly reports may need to prepare and have reviewed the prior-year quarterly statements it skipped.15 Read the final text if one is adopted.

ASU 2025-07: why milestone-linked contracts may leave derivative accounting

A payment that depends on a future event can technically look like a derivative, a contract whose value moves with some outside variable. That would mean accounting at fair value, roughly what the item would sell for today, with swings through earnings. The FASB says questions had arisen about long-standing deals, naming research and development funding arrangements among them.11

ASU 2025-07 excludes non-exchange-traded contracts whose variables are based on operations or activities specific to one of the parties. Its text names events such as obtaining regulatory approval or achieving a product development milestone, says it does not matter whether the outcome is within the entity's control, and works a drug research funding arrangement as its first example. Variables based on market rates and prices stay outside the exception, among other listed cases.11

Before the change, a memo on a contingent payment had to walk through that derivative analysis, as Deloitte's chapter on asset acquisitions shows.16 After adoption, the same memo should test the new exclusion and its exceptions.

This guide is written to US GAAP. Companies reporting under IFRS Accounting Standards should check each point separately. The International Accounting Standards Board, or IASB, is reviewing IAS 38, its intangible assets standard; on October 27, 2026 it discussed recognition requirements and made no decisions.17

On the US side, the FASB considered and decided against technical agenda projects on alternative funding arrangements, including research and development funding, in the first quarter of 2026,18 and on intangibles on May 13, 2026.19 Those chair reports run through June 30, 2026, the latest we could read.

ASC 606 milestone accounting, worked through: why $40.0 million on approval stays out of revenue

In shortThe five steps of ASC 606 turn a license into a revenue figure. The hard one is usually step three, the price. A payment due on regulatory approval is variable consideration, and it enters revenue only if a significant reversal is probably not going to happen. For a new drug, that often means waiting for the regulator.

The license from the opening example has four money terms in its agreement: $75.0 million within 30 days, $40.0 million on approval in Japan, royalties of 12% to 18% on net sales, and clinical supply at cost plus 10%. Here is how each runs through the standard's five steps, which are set out at ASC 606-10-05-4.3

The "probable" sentence in ASC 606-10-32-11, and the misreading to avoid

A payment that depends on an uncertain event is variable consideration, and it has to be estimated.3 When there are only two outcomes, paid or unpaid, the standard says the "most likely amount" may be an appropriate estimate.3 Then comes the limit. ASC 606-10-32-11 includes the amount "only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur".3 The Codification's glossary defines probable as likely to occur.3

Read that again with the hurdle in mind. You need to be able to say a big reversal is likely not to happen. A loose summary lets an uncertain amount in when the odds are unclear, and the real test keeps it out.

What booking the milestone early would do to the third quarter

The quarterly re-check, and how royalties, upfront timing and supply differ from the milestone

Leaving the milestone out is a conclusion for today. ASC 606-10-32-14 requires an update at the end of each reporting period, including whether the estimate is still constrained.3 When a regulator's decision lands after quarter end and before the statements are issued, Deloitte points to the subsequent events guidance in ASC 855.21

• Royalties. The constraint does not apply. A royalty on a license of intellectual property counts as revenue when the later of two things happens: the sale occurs, or the obligation is satisfied.6
• Timing of the upfront payment. A license can transfer at a point in time or over time, depending on what it grants.6 A functional license grants rights to intellectual property that works as it stands, and is usually recognized at a point in time. Treating rights to a developed molecule as functional supports the example's single date, and the memo has to show that reasoning.
• Clinical supply. An option to buy more is a separate obligation only if it gives a material right, meaning a discount the customer would not otherwise get.3 The example leaves this open with a named person, and says it does not change the third-quarter amount.

The ASC 805 screen test and acquired IPR&D: how a $410 million purchase becomes a $384.5 million charge

In shortAccounting sorts the purchase of a company into one of two kinds: a business combination or an asset acquisition. If substantially all the value sits in one asset, the deal is an asset acquisition: no goodwill (the premium paid above the identified assets), deal costs added to cost, and acquired research charged straight to expense when it has no other use. Those differences decide the size of the charge and when it lands.

In the guide's second example, Northwind buys Tamsin Biosciences on September 22, 2026. It pays $410.0 million in cash, including $12.4 million held in escrow for the three founders, plus $6.8 million of its own deal costs. A further $350.0 million may follow: $75.0 million when the first patient is dosed in a Phase 3 study, $125.0 million when the application is accepted and $150.0 million on approval. A preliminary valuation puts the non-cash assets at $431.0 million.

Step one, the screen: is nearly all the value in one asset?

ASC 805-10-55-5A says that if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, or a group of similar ones, the set is not a business. Gross assets leave out cash, deferred tax assets and goodwill arising from deferred tax liabilities.7 Deloitte says "substantially all" is generally read as 90% or more, while warning that the FASB did not intend a bright line and that a result close to 90% calls for judgment.16

Business combination or asset acquisition: seven lines of accounting that change

Condensed from Deloitte's comparison table.16

Measuring the acquired R&D charge, line by line

The calculation can be checked by hand. Cost is what you paid, plus direct deal costs. Spread it over the non-cash assets by their relative fair value, and the share falling on the two research programs is expensed, because under ASC 730-10-25-2 intangibles acquired for research are capitalized, meaning held as assets, only if they have alternative future uses beyond the project at hand.8 The two programs hold $413.5 million of the $431.0 million, or 95.9%.

Fictional example. Figures follow the sample memo shown in Part B.

Up to $350.0 million of milestones, and nothing booked at close

ASC 805-50 says liabilities incurred are part of the cost of an asset acquisition, but gives no specific guidance on contingent consideration. Deloitte reads the guidance this way: if it meets the definition of a derivative it goes to fair value; otherwise ASC 450 may require recognition when a liability is probable and can be reasonably estimated.

Deloitte adds that practice varies, with others waiting until the contingency resolves, that it accepts either approach, and that a payment based on regulatory approval is generally not considered probable until the contingency is met.16 In the example, no milestone is probable at close, so nothing is recorded. When one becomes probable it is expensed, because the asset it relates to was expensed. The memo should also run the derivative test, now with the ASU 2025-07 exclusion in view from its effective date.11

Founder retention payments: when your written policy and your last signed memo disagree

In shortA payment to sellers that disappears if they leave generally counts as pay for future work. The example's written policy says so, but a signed memo from two years earlier treated a similar payment as part of the price. Finding that conflict before the auditor does is the hard part. Deciding it belongs to a named person.

Tamsin's $12.4 million sits in escrow, released to the three founders only if each still works for Northwind 18 months after closing. Forfeited amounts come back. Under ASC 805-10-55-25(a), for a business combination, a contingent payment that is automatically forfeited if employment ends is compensation for later service, and PwC's guide says so in those terms.22 This deal is an asset acquisition, so the paragraph can apply only by analogy, and PwC's page does not address that case. The company's own policy, section 7.2.6, takes the analogy.

The difficulty is history. A memo signed in November 2024 for an earlier purchase, Elmstead Bio, put $4.0 million of stay-conditioned founder payments into the price, on the ground that it was negotiated as part of the price. A prior controller signed it. Nobody revised the policy, and nobody flagged the difference. A reviewer who only reads the policy misses it, and a reviewer who only reads the last memo copies it.

What the memo owes a reader on this judgment

• Both sources, quoted side by side. The policy section and the earlier memo, each with its date and signer.
• The indicator from the literature. Automatic forfeiture points to compensation.22 PwC also says all the indicators should be considered, and works through payments shared among selling shareholders.22
• Why the earlier memo does or does not apply. Different facts can justify a different answer. "That was then" cannot.
• What happens to the policy. If practice changed, the manual needs an update, or the exception needs a record.
• The name and date of the person who decided. A judgment recorded with a reason can be challenged and defended, and a reviewer has something specific to test.

Collaboration cost shares, embedded leases, pre-launch inventory and priority review vouchers: four more recurring calls

In shortBeyond licenses and acquisitions, life sciences finance teams keep meeting the same four questions. Each has a clear starting paragraph and a judgment that depends on facts: who the customer is, who controls a production line, how likely approval is, and what you intend to do with a priority review voucher. That is an FDA award, which qualifies a later application for a 6-month review in place of the standard 10 months and can be sold between companies.8

Real restatements over milestones and performance obligations, and the errors behind them

In shortPublic filings show the same kinds of error: a milestone booked at once that belonged across two obligations, one performance obligation that should have been two, a method of measuring progress that had to change. Each of the three filings below also reported a material weakness in internal control. We describe them only as the companies' own filings do.

When a company concludes that earlier statements can no longer be relied on, it files a Form 8-K, a current report to the SEC, under Item 4.02. A performance obligation, a term that runs through them, is a promise to transfer something distinct to a customer. These three filings all concern license or collaboration revenue. CytomX's names ASC 606; the other two do not cite it.

Seven errors a reviewer of a position memo can look for

Small amounts can still matter. SEC Staff Accounting Bulletin 99 says relying only on a percentage threshold has no basis in the accounting literature or the law, and lists qualitative factors, including whether a misstatement masks a change in earnings or other trends, or changes a loss into income.26 A milestone that turns a loss into a profit for one quarter is the kind of case those words describe.

What auditors, inspectors and SEC staff test in a memo, and where they keep finding problems

In shortAudit firms, their inspectors and SEC staff all read the results of these judgments. Audit inspectors have seen deficiency rates fall sharply, to 23% for 2025. SEC staff comment letters still rank revenue among the top topics. Nearly every company reporting a material weakness cites documentation, and most now cite a shortage of accounting resources or expertise.

Audit inspection results, and why estimates are in the spotlight

The Public Company Accounting Oversight Board, or PCAOB, inspects audit firms. Part I.A deficiencies are cases where an auditor failed to obtain enough evidence for an opinion, so the audit firm's own work is what inspectors grade.

In its 2024 review, PCAOB staff said their most common observations on estimates concerned revenue recognition such as standalone selling price (what an item would sell for on its own), accounts affected by business combinations including fair value and contingencies, and forecasts.27 Those are the topics of this guide. An auditor under that scrutiny asks the company for support, and the memo is where that support starts.

Deadlines are shortening as well. As amended with AS 1000 and approved by the SEC in August 2024, the PCAOB's documentation standard (AS 1215.15) cuts the time to assemble the final audit file from 45 days to 14 days. It applies to audits of fiscal years beginning on or after December 15, 2024, except at firms that gave audit opinions for 100 or fewer issuers in 2024, where it applies a year later.29

We found no postponement as of November 3, 2026. Our reading: with less time after the report, auditors have more reason to want memos earlier and in final form.

Revenue and research rank near the top of SEC staff comments

SEC staff must review each registrant's filings at least once every three years, and they put their questions in comment letters.4 EY quotes a staff comment to a company with collaboration and license agreements, asking how it considered splitting revenue from up-front fees, option fees, research funding, milestones and royalties. It also reports that staff has historically asked registrants to support their conclusion that an acquisition did or did not meet the definition of a business.4

The judgment reaches earnings releases too. EY lists up-front and milestone payments, and acquired IPR&D charged to R&D in an asset acquisition, among the adjustments staff has historically objected to in non-GAAP measures, the adjusted figures companies publish beside their GAAP results.4

Why material weaknesses keep pointing to documentation and people

A material weakness is a serious gap in internal control over financial reporting. KPMG's 2025 study counted 238 companies disclosing one in 3,307 annual reports, about 7%.31

Why memo volume tracks biopharma deal volume, and what 2025's $232 billion in licensing means for finance

In shortEach license, acquisition or collaboration opens several accounting questions. IQVIA put 2025 licensing deal value at a ten-year high. No one publishes how many memos that produces, or the size of the market for memo software, so count your own deals and the questions they raised.

Total deal value can sit far above the cash paid at signing. IQVIA's own examples include a license worth up to $6 billion with $1.25 billion upfront, and an alliance worth up to $12 billion with $500 million upfront.33 For the accountant, the contingent part is what makes the work hard. A single deal can raise several separate questions, usually in the same close.

Where AI helps in technical accounting research, where it stops, and what regulators have said so far

In shortAI is good at finding passages, reading contracts and drafting in a set format. Accountable judgment stays with people, and PCAOB staff reported firms saying the same. No rule addresses AI memos specifically. The working frame is internal control over financial reporting, with COSO's 2026 guidance as the newest reference. Pharma's GxP rules, the good-practice rules for making and testing medicines, do not reach this work.

What regulators and standard setters have said

The evidence on accuracy: useful, and thinner than vendors imply

The closest rigorous test we found comes from law. A preregistered study, one that fixed its method in advance, of AI legal research tools built on retrieved documents found that the tools invented or misstated material between 17% and 33% of the time, less often than a general chatbot.40 That is a different field and a test of particular tools at one point in time. We found no equivalent independent study for accounting research.

The lesson carries over anyway: a citation beside a sentence proves little until someone or something checks the sentence against the passage.

In accounting more broadly, a Stanford and MIT study of 277 accountants and 79 small and mid-sized firms using AI tools found monthly statements finalized 7.5 days faster, and 62% of accountants worried about AI errors.41 That work concerns bookkeeping and the close. It does not measure memos.

How finance teams write technical accounting memos today: six roles, five steps and an estimated nine hands-on hours

In shortA deal accountant raises the question, a technical accountant researches and drafts, and the controller signs. By hand, the hours go on finding precedent, reading contracts and writing. No published time study exists. The nine hours below are an estimate for you to replace, and elapsed time is usually much longer because the memo waits on people.

Six roles around a position memo, from deal accountant to external auditor

From a closing deal to a signed position in about ten days, in this example

Nine estimated hours on one memo, split by task

Your own team, outside advisers, research libraries or memo software: who produces position memos

The $40.0 million Japan milestone: a cited answer in seconds, with the ASC 606 memo drafting beside it

In shortThis is the example from the top of the page, inside the product. On October 7, working day 5 of the close, Dr. Maya Chen, the assistant controller, asks her question in plain words. AI agents, programs that each do one job, read the license, the policy, an earlier memo and the ASC 606 summary. Every sentence comes back with a citation, and memo M-313 lays itself out in the standard's five steps with step 3 marked as the deciding step.

1

The question desk opens on the work

The home screen has three panes. Questions sit on the left, the conversation in the middle and the memo on the right. Here the question from Sam Patel, the deal accountant, on the Tamsin purchase is already answered, and memo M-311 is drafted through step 4. Three questions show a conflict between policy and practice, and one has gone to a person.

At the bottom left the screen says what it searches: 63 policies, 286 memos, 41 audit committee papers and 9 standards topics.

2

A new question shows the three memo layouts

Omar Haddad, the alliance accounting lead, needs the Sakuradai position before the auditors' date. Maya starts a new question. The panel on the right shows the layouts a memo can take: ASC 606's five steps, the ASC 805 asset acquisition analysis, and ASC 842's lease test.

The structure follows the standard the question falls under, and each step keeps the paragraphs it relies on.

3

Each agent's step shows as it runs

Maya asks: "Is the $40M Japan approval milestone in the Sakuradai license variable consideration, and does any of it go into Q3 revenue?" The question router labels it ASC 606, Sakuradai license, Q3 2026. The contract reader pulls sections 3.1, 3.2 and 3.4. The standards researcher finds the paragraphs. The retriever brings policy section 3.4.2 and the Kestrane memo of February 2025. The conflict checker finds that policy and practice agree here.

4

Six sentences, ten citations, and the memo in five steps

The answer takes 6.3 seconds on the sample: six sentences, ten citations, four sources, 93% confidence. The $40.0 million is variable, is estimated at the most likely amount, and is constrained because approval rests with Japan's regulator. Third-quarter revenue from Sakuradai is the $75.0 million upfront only, reviewed again at each quarter end, the same way the Kestrane out-license was handled in 2025.

Step 3 on the right carries the label "the deciding step".

5

Clicking a paragraph reference opens its source

Maya clicks 606-10-32-11 in step 3, and the Source tab opens the company's plain-language summary with the passage highlighted.

Read the real paragraph too. This screen shows the sample company's own summary, which says "included only when a significant reversal is not probable". The standard's wording is stricter: "only to the extent that it is probable that a significant reversal ... will not occur".3 Section 4 explains the difference. Summaries in your library deserve the same check. The Codification itself is free to read, and its copyright stays with the foundation, so the product cites by paragraph and summary.2,13

6

The memo opens as a document for the audit file

M-313 opens addressed to the audit file. Sections run down the left, and the evidence, review notes and activity down the right. The checks list reads 18 citations from 4 sources, all verified, with paragraph-level references and an alternatives section. The dated sign-off is still pending.

The supply terms stay open with Omar as a possible material right, and the memo says that does not change the third-quarter amount.

7

The deciding step, the alternatives, the conclusion

Lower down, step 3 reaches its conclusion. The alternatives section then rejects two views: including the $40.0 million now as the most likely amount, and spreading the upfront over the development period. The conclusion says Q3 revenue is $75.0 million and the milestone is left out, and reassessed at each quarter end.

The $12.4 million founder payment: the conflict surfaced, a person decides, and the controller and chief accounting officer sign

In shortOn the Tamsin purchase the agents find a real conflict: the written policy and a signed memo point different ways. The product shows both, with each option's effect on the charge, and stops. Maya decides and records her reason. The memo then writes the remaining sections, and because the charge is above $100 million, both the controller and the chief accounting officer (CAO) sign.

1

Policy and practice, flagged under the answer

Under the answer sits a callout: policy section 7.2.6 treats payments that depend on staying as pay for future work, while the Elmstead memo put a similar payment into the price. Every statement carries its citation. The key facts below give the screen test at 93.3%, against the company's 90% threshold, and the acquired R&D as a range that depends on the decision.

2

Step 5 of the memo becomes a decision card

Option A follows the policy: $384.5 million of acquired R&D in the third quarter, with $12.4 million of compensation over 18 months. Option B follows the earlier memo: $396.4 million, recorded as a policy exception. The card suggests a reason, which Maya can edit. The agents never choose, and the sections after this one wait for her decision.

Section 6 of this guide explains why automatic forfeiture points toward option A.22

3

Her decision goes on the record

Maya uses option A. The memo records her name, the date and her reason: the escrow is forfeited if a founder leaves before 18 months, so it pays for future services. The memo drafter then writes the alternatives rejected and the conclusion, and the citation checks run again.

4

The impact and the journal entry

The financial statement section gives $384.5 million of acquired IPR&D on September 22, $0.2 million of compensation in the third quarter and the remaining $12.2 million over the stay. Up to $350.0 million of milestones is disclosed as a contingent payment. The journal entry balances at $431.4 million on each side, and the figures tie to the calculation in section 5.

5

Above $100 million, two signatures

The charge is over the limit in Settings, so memo M-311 goes to Priya Ranvelle, the corporate controller, and Ruth Adeyemi, the chief accounting officer. The signature's meaning reads "Approved as management's position for Q3 2026".

6

Signed, locked, ready for the auditor

All three names now show dates, and the version becomes 1.0. The next action is sharing the memo with the external auditor, who tests it independently. Dana Okafor in internal audit can read the memo, the evidence and the activity trail at any time.

The memo register, policy gaps and citable library that sit behind each technical accounting answer

In shortFour more screens keep the quarter under control: a register of every memo with its stage and signers, a list of places where the policy and practice part ways, a versioned library of what may be cited, and a dashboard. Settings hold the answer rules and the signing limits.

Who drafts a position memo and who answers for it: seven agents, a preparer, a controller and a CAO

In shortEach agent has one job and one thing it must never do. People decide every judgment and sign every memo. Below are the agents, the rules around them, what goes in and comes out, the systems the solution works with, and the only outcome numbers we state, which are design targets.

The memo agents, and what each must never do

The product's solution page counts six specialist agents. The seventh name here, the contract reader, runs as a step in each run.

Maker, checker and signer: the rules people keep

From contracts and signed memos to a position memo: what the solution reads and writes

Systems a technical accounting rollout connects to

The two technical accounting outcome targets we state

Both are design goals, shown on the sample dashboard, for you to measure in your own pilot. No customer result sits behind either.

The price of a late or weak position memo: technical hours, audit rework and restated quarters

In shortThe hours are the smallest part. Your larger exposure is a judgment that goes wrong and comes back as a restatement or a material weakness, which public filings show happening over a single milestone. No one publishes the cost per memo, so start with what you can measure in a week.

Timing three memos and tracing ten citations to find your baseline

The restated quarter, the key person and other costs a memo calculator misses

Preparer hours and faster answers against the tool's cost: the return on technical accounting memo automation

In shortPut in your own numbers. Every default marked illustrative is an assumption to replace. On the defaults, hours alone do not cover a yearly cost of $100,000: the case tips at roughly 830 hours saved. A small team with few deals may be better served by an organized memo library and a good search tool. The stronger case rests on the conflicts found and the record kept.

Four levers on a memo tool's payback, from preparer time to conflicts caught

Your hours back on 40 memos and 400 questions a year

On the defaults, 40 memos and 400 questions free 740 hours, worth $88,800, which falls $11,200 short of the assumed $100,000 tool cost. At 60 memos and 600 questions, the same assumptions free 1,110 hours and clear it by $33,200. Nothing in these defaults comes from a study. The sample company on the product's screens fields 214 questions a quarter from about 200 finance staff, far above these defaults, which is a reminder to count your own.

A readiness check for technical accounting: memo archive, policy manual, contracts and sign-off rules

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

What to do at each score: gather the memos, replay past questions or plan the rollout

Ten questions for any technical accounting memo software vendor, including us

In shortMost demonstrations look good on a question the vendor chose. Bring a question you have already answered, with a trap in it, and ask these. A strong vendor will welcome the test.

Testing memo automation on twenty questions you already answered, then one live close

In shortTest it on past questions with known answers, then run one quarter close in parallel. Keep your usual process until the numbers say otherwise, and tell your auditor before you start. Avoid starting in a close week.

Eight things to measure in a position memo pilot

Technical accounting memo questions answered: ASC 606 milestones, asset acquisitions, IPR&D, auditors and AI

In shortQuestions finance teams search for, each answered on its own.